Condition
Higher-risk Myelodysplastic Syndromes
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT07155226Phase 1Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT06196203Phase 2RecruitingPrimary
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
NCT06471946Phase 1RecruitingPrimary
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Showing all 3 trials